Zobrazeno 1 - 10
of 425
pro vyhledávání: '"B, Gil Extremera"'
Publikováno v:
Revista Clínica Española (English Edition). 218:137-141
Clinical trials are essential tools for the progress of clinical medicine in its diagnostic and therapeutic aspects. Since the first trial in 1948, which related tobacco use with lung cancer, there have been more than 150,000 clinical trials to date
Publikováno v:
Revista Clínica Española. 218:137-141
Clinical trials are essential tools for the progress of clinical medicine in its diagnostic and therapeutic aspects. Since the first trial in 1948, which related tobacco use with lung cancer, there have been more than 150,000 clinical trials to date
Autor:
B. Gil Extremera
Publikováno v:
Revista Clínica Española. 215:240-243
Publikováno v:
Revista clinica espanola. 218(3)
Clinical trials are essential tools for the progress of clinical medicine in its diagnostic and therapeutic aspects. Since the first trial in 1948, which related tobacco use with lung cancer, there have been more than 150,000 clinical trials to date
Autor:
Erik Stroes, John R. Guyton, Norman Lepor, Fernando Civeira, Daniel Gaudet, Gerald F. Watts, Marie T. Baccara‐Dinet, Guillaume Lecorps, Garen Manvelian, Michel Farnier, K. Kostner, S. Lehman, O. Descamps, L. Gheyle, C. Mathieu, J. Bergeron, T. Elliott, G. Girard, A. Gupta, G. Hoag, J. Hove, J. Jeppesen, J.H. Kjærulf, K. Klarlund, K.K. Thomsen, D.C.G. Basart, A. Kooy, A. Liem, H. Swart, R. Troquay, J Van Het Hof‐Wiersma, P. Viergever, F. Visseren, R.N. Doughty, R. Scott, C. Calvo, J.L. Díaz‐Díaz, F. Fuentes, B. Gil‐Extremera, C. Jericó, L. Matas Pericas, J.D. Mediavilla Garcia, D.E. Bolster, M. Koren, M. El Shahawy, G. Vardi, D. Weinstein, K. Zuzarte, Henry Ginsberg, Jennifer G. Robinson, Daniel J. Rader, Christopher P. Cannon, Helen Colhoun, John J.P. Kastelein, Yong Huo, Anders Olsson, David Waters, Dominique Larrey, Robert S. Rosenson, Peter A. Patriarca, Geert Molenberghs, Pierluigi Tricoci, Kenneth W. Mahaffey, Renato D. Lopes, Bimal R. Shah, Rajendra H. Mehta, Matthew T. Roe, Zubin Eapen, Luciana Armaganijan, Adriana Bertolami, Sergio Leonardi, Bradley J. Kolls, J. Dedrick Jordan, Grégory Ducrocq, Etienne Puymirat, Robin Mathews
Publikováno v:
Journal of the American Heart Association, 5(9). Wiley-Blackwell
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 9, Pp n/a-n/a (2016)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 9, Pp n/a-n/a (2016)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Background The PCSK 9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol ( LDL ‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated a
Autor:
F. Barucq, B. Minescu, S. Slabic, A. Ivleva, Y. Svyshchenko, Catalina Arsenescu Georgescu, R. Marple, N. Gotcheva, A. Patron, F. Robin, P. Touzet, T. Lívia, K. Crump, H. A. Punzi, M. Pouget, I. Vykhovanyuk, D. Lecaignard, J. Y. Yang, O. Korzh, J. M. Hill, A. Vishnevsky, B. D. Forestier, V. Shatilo, L. Kononenko, E. Hannoush, A. MacAgno, B. Gil-Extremera, G. P. Tatu-Chitoiu, J. L. Diaz, B. Perrin, E. Jordan, P. J. Lane, R. Combet, C. Fivel, D. Taminau, I. Karen, R. Struble, P. Causse, M. Ripoll, L. Yena, M. Bismuth, C. Giraldi, D. Raev, A. Faynyk, I. Horný, M. Bourgoin, L. Jagminas, I. Manitiu, I. Gordeev, O. Jerábek, V. Mincheva, J. P. Jacquet, N. Breton, M. Cristea, P. Chalaux, L. Levinson, Joel M. Neutel, T. Tyurina, C. A. Percheron, Ludwin Ley, B. Lemarie, J. Oliván, S. Milanov, V. András, A. Khennouf, D. Gaita, A. Martynov, S. Hojerová, L. Jappy, B. Geoffray, D. G. Cheung, R. D. Eyzaguirre, J. C. Deme, M. Depoisier, Richard Vinisko, N. Gabriella, G. Martocq, C. J. Mello, V. Kolíková, R. E. Tidman, J. Gonsorcík, B. Goloborodko, Y. Sirenko, N. R. Patel, N. Zlatareva, P. Cayron, M. H. Kim, A. Filippov, P. Záreczky, M. Hranai, J. Nagel, Björn Dahlöf, G. Venturini, B. Dimon, M. Y. Lee, M. H. Vuong, Z. Károly, C. G. Park, N. Bittar, S. M. Kang, S. H. Baek, B. Michalak, G. Pencheva, A. M. Salajan, M. Flosi, J. C. Kuchar, Henry R. Black, I. Benedek, B. Zehnder, I. László, R. J. Graf, G. Aroutiounov, D. Sacareau, O. Geronimi, S. Dragulescu, P. Michellier, P. Ibolya, V. Zadionchenko, Z. Krumlov Lorenc, S. Petranov, A. Chaleon, T. Donova, Holly Defeo, M. Peterka, D. E. Webster, D. R. Ricci, D. B. Jack, R. L. Eddy, J. J. Roger, M. B. Samson, R. Judit, A. Chalvignac, J. L. Tovar, J. L. Pool, E. B. Portnoy, V. Kostenko, D. Lefort, S. Stoimenov, S. Judit, M. Repin, G. Rouviere, Y. Khronusova, B. Kanna, F. Henriot, B. Goloshchekin, Giusepe Mancia, O. Karpenko, N. Winer, H. M. Kwon, L. Ruffini, J. Munoz, F. Lacoin, A. Matei, I. Kraiz, F. Pont, E. Nabedian, P. Ferenc, J. Wayne, A. Queguiner, E. Zídková, D. Zimmermann
Publikováno v:
The Journal of Clinical Hypertension. 14:206-215
This 8-week, randomized, double-blind, controlled study compared efficacy and tolerability of telmisartan/amlodipine (T/A) single-pill combination (SPC) vs the respective monotherapies in 858 patients with severe hypertension (systolic/diastolic bloo
Autor:
B. Gil Extremera
Publikováno v:
Revista Clínica Española. 210:361-364
Autor:
H. Giezek, Alice R. Mao, S. Shah, Richard Ceska, C. McCrary Sisk, J. F. Paolini, B. Gil-Extremera, K. Vandormael, Darbie Maccubbin
Publikováno v:
International Journal of Clinical Practice. 64:727-738
Summary Background: Co-administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction. However, niacin is underutilised because of the side effects of flushing, mediated primarily by prosta
Autor:
M.A. de Cruz Benayas, E. Viseras Alarcón, B. Gil Extremera, J.A. Maldonado Jurado, A. Maldonado Martín
Publikováno v:
Hipertensión. 25:240-244
Objetivo El objetivo de este trabajo ha sido estudiar la influencia de la historia familiar de hipertension en la edad de aparicion de la enfermedad en los pacientes estudiados. Pacientes y metodos Analizamos un grupo de poblacion hipertensa espanola
Publikováno v:
Hipertensión y Riesgo Vascular. 22:133-138
La hipertension refractaria tiene una prevalencia del 1% a 3% y corresponde a los casos que no responden al tratamiento farmacologico y medidas generales: dieta, ejercicio fisico y restriccion en la ingesta de sal. El sindrome de apnea obstructiva de